102871-92-1

Basic information

• Product Name: 4-Ethoxy-1-Methyl-2-nitrobenzene
• Synonyms: 4-Ethoxy-1-Methyl-2-nitrobenzene
• CAS NO: 102871-92-1
• Molecular Formula: C₉H₁₁NO₃
• Molecular Weight: 181.18854
• Mol File: 102871-92-1.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-Ethoxy-1-Methyl-2-nitrobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Ethoxy-1-Methyl-2-nitrobenzene(102871-92-1)
• EPA Substance Registry System: 4-Ethoxy-1-Methyl-2-nitrobenzene(102871-92-1)

Safety Data

• Hazardous Substances Data: 102871-92-1(Hazardous Substances Data)

Upstream product

• 64-67-5 diethyl sulfate 
• 2042-14-0 4-methyl-5-nitrophenol 
• 75-03-6 ethyl iodide 

Downstream Products

• 75785-11-4 5-ethoxy-2-methylaniline 
• 103440-98-8 4-ethoxy-2-nitro-benzoic acid 
• 99843-81-9 (4-ethoxy-2-nitro-phenyl)-pyruvic acid 
• 100373-63-5 2-Nitro-4-aethoxy-benzaldiacetat 
• 103989-09-9 6-ethoxy-1H-indole-2-carboxylic acid 
• 99358-08-4 4-ethoxy-2-nitrobenzaldehyde 
• 861337-54-4 1-(bromomethyl)-4-ethoxy-2-nitrobenzene 
• 1380068-81-4 tert-butyl {(1S)-2-[4-(6-ethoxy-2H-indazol-2-yl)-3-fluorophenoxy]-1-methylethyl}carbamate 
• 1380066-94-3 N-{(1S)-2-[4-(6-ethoxy-2H-indazol-2-yl)-3-fluorophenoxy]-1-methylethyl}acetamide 
• 876738-20-4 C₂₁H₂₃N₃O₃S 
• 37865-86-4 6-ethoxy-1H-indole 
• 1613505-09-1 6-ethoxy-5-(2-trifluoromethylphenyl)-1H-indazole 

Relevant articles and documents

Discovery, optimization, and biological evaluation of 5-(2- (trifluoromethyl)phenyl)indazoles as a novel class of transient receptor potential A1 (TRPA1) antagonists

A high throughput screening campaign identified 5-(2-chlorophenyl)indazole compound 4 as an antagonist of the transient receptor potential A1 (TRPA1) ion channel with IC50 = 1.23 μM. Hit to lead medicinal chemistry optimization established the SAR around the indazole ring system, demonstrating that a trifluoromethyl group at the 2-position of the phenyl ring in combination with various substituents at the 6-position of the indazole ring greatly contributed to improvements in vitro activity. Further lead optimization resulted in the identification of compound 31, a potent and selective antagonist of TRPA1 in vitro (IC50 = 0.015 μM), which has moderate oral bioavailability in rodents and demonstrates robust activity in vivo in several rodent models of inflammatory pain.

BICYCLIC COMPOUND

The present invention provides a compound having an ACC inhibitory action, which is useful as an agent for the prophylaxis or treatment of obesity, diabetes and the like, and having superior efficacy. The present invention relates to a compound represente

HETEROCYCLIC NON-PEPTIDE GNRH ANTAGONISTS

A compound of formula (I): wherein either B is absent and A and Z are the same or different and are each hydrogen, halogen, alkyl, hydroxy, alkoxy,-CN,-C(Rc)2OH,-N(Rd)C(=X)Rc,-C(=X)N(Rc)(Rd),-S(O)m-Rc,-N(Rc)(Rd)S(O)2,-S(O)2N(R c)(Rd),-N(Re)2, aryl optionally substituted with Ra or-O-aryl optionally substituted with Ra; or B is present and is-(CH2)n-,-C(Rb)2-or-O-, or B taken together with A or Z can be-C=C(Rb)-,-C(Rb)=C-,-CH2-CH(R b)-or-CH(Rb)-CH2-; D is-O-or-S(O) m,-; E is a bond or is-(CH2)n-,-N(R d)-,-(CH2)nN(Rd)-or-N(R d)(CH2)n-; F is-C(=X)-; G is-(CH2 )n-,-N(Rd)-,-(CH2)nN(R d)-or-N(Rd)(CH2)n; J is a bond,-O-,-N(RC)C(=X)-,-C(=X)N(Rc)-,-S(O)m,-,-N(Rc)S(O)m-,-S(O)nN(Rc)-,-N(Re)-or-N(Rg)(Rh); K is a bond, alkylene, cycloalkylene, cycloalkenylene, arylene, heterocycloalkylene, heterocycloalkylene or heteroarylene; and L is hydrogen or a terminal group; has therapeutic utility.